Venus Remedies has received marketing authorisation in Indonesia for its antibiotic combination Ceftazidime + Avibactam, granted by the relevant Indonesian drug regulatory authority. This approval marks the first marketing authorisation for Ceftazidime + Avibactam for the company in lndonesla. The product is indicated for the treatment of serious infections caused by multi-drug-resistant gram-negative pathogens, including complicated intra-abdominal infections and complicated urinary tract infections.
This authorisation enables the company to commercialise the product in Indonesia through its existing distribution partnerships and is expected to enhance the company's presence in a strategically important market for anti-infective. The development is aligned with the company's strategy of expanding its footprint in South-East Asia and strengthening its portfolio of high-barrier-to-entry therapies.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
